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Abstract 45 
Background: Hormone replacement therapy may be beneficial for cardiovascular 46 
disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective 47 
estrogen receptor modulators. The aim of this study was to evaluate whether soy 48 
isoflavones had an effect on CVR markers.  49 
Methods: The expected 10-year risk of cardiovascular disease and mortality were 50 
calculated as a secondary endpoint from a double blind randomised parallel study 51 
involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early 52 
menopause who were randomised to 15g soy protein with 66mg isoflavone (SPI) or 53 
15g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between 54 
meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles 55 
were used to calculate CVR using the Framingham CVR engine.  56 
Results: SPI treatment resulted in a significant reduction in the metabolic parameters 57 
and systolic blood pressure compared to SP  (p<0.01).  There were no changes in fasting 58 
lipid profile and diastolic blood pressure with either treatment. At 6 months, changes in 59 
these parameters with SPI treatment were reflected in a calculated 27% (p<0.01) 60 
reduction in 10 year coronary heart disease risk, a 37% (p<0.01) reduction in 61 
myocardial infarction risk, a 24% (p<0.04) reduction in cardiovascular disease and 42% 62 
(p<0.02) reduction in cardiovascular disease death risk.  63 
Conclusions: Supplementation with soy protein with isoflavones for 6 months 64 
significantly improved CVR markers and calculated CVR at 6 months during early 65 
menopause compared to soy protein without isoflavones.  66 
ISRCTN registry – ISRCTN34051237 67 
  68 
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Introduction 69 
Cardiovascular disease (CVD) is uncommon in premenopausal women, but at the 70 
menopause there is an increased and recognised cardiovascular disease risk (CVR) for 71 
coronary heart disease (CHD) (1). Analysis of the Women’s Health Initiative study 72 
suggested that women treated with hormone replacement therapy (HRT) did not have 73 
an increased risk of CHD and indeed it may result in reduced CVR if estrogen was 74 
given within 10 years of their menopause compared to those who were not on HRT 75 
(2). Soy isoflavones can act as selective estrogen receptor modulators that may have 76 
beneficial effects on CVR indices (3, 4). Although there are studies comparing the 77 
effect of whole soy, soy protein and isoflavones showing variable effect on 78 
cardiovascular disease risk markers (5-8), there are no studies looking into the effect 79 
of combined soy protein and isoflavones with isoflavone free comparator in post-80 
menopausal women.   81 
The isoflavones are heterocyclic phenols that mainly comprise genistein, daidzein and 82 
glycitein that have both in vitro and in vivo estrogenic effects due to their structure 83 
that is similar in structure to 17 beta estradiol (3).  Equol is produced by the 84 
metabolism of the isoflavone daidzein by intestinal bacteria. In Western countries, 85 
30% to 50% of individuals metabolize daidzein into equol and are known as equol 86 
producers. It has been suggested that equol production may be the source of benefit 87 
from isoflavones(9).  Isoflavones can potentially improve cardiovascular health by 88 
maintaining endothelial integrity and increase nitric oxide, prostacyclin release 89 
leading to endothelium-dependent vasodilation (10). Isoflavones can also inhibit 90 
vascular smooth muscle proliferation and contraction by activating cAMP- and 91 
cGMP-dependent pathways and decreasing Ca2+ influx and release (10). Isoflavones 92 
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have also been shown to reduce oxidative stress, inhibit angiogenesis and attenuate 93 
vascular inflammation (10). 94 
 95 
The Framingham Risk Score is an algorithm commonly used to estimate the 10-year 96 
cardiovascular risk of an individual without diabetes inputting various variables 97 
including age, sex, smoking status, total cholesterol, LDL-cholesterol, systolic blood 98 
pressure and use of anti-hypertensive medications (11). This has been used in 99 
prospective studies to assess the cardiovascular risk (12). We have previously shown 100 
a reduction in cardiovascular disease risk markers using this soy/isoflavone 101 
preparation in men (4). Therefore, a post hoc analysis of cardiovascular risk using the 102 
Framingham Risk Score was undertaken in this randomised, double blind, parallel 103 
study in which the primary end point was a change in bone turnover markers (13). 104 
Materials and methods 105 
Two hundred Caucasian women from the Hull and East Riding of Yorkshire, UK within 106 
two years of the onset of their menopause (FSH greater than 20 mU/L and amenorrhoea 107 
for one year) were recruited after screening 334 women who responded to newspaper 108 
advertisements (13). None of the patients were taking any prescription or over the 109 
counter medications. Women with a previous history of medication that could interfere 110 
with bone metabolism including steroids, bisphosphonates, thyroxine or hormone 111 
replacement therapy were excluded. All women were non-smokers and no subject had 112 
type 2 diabetes. Women with significant hepatic or renal impairment, who were allergic 113 
to soy products and those who had antibiotic exposure in the three months prior to the 114 
study, were also excluded. The study was undertaken at the Diabetes, Endocrinology 115 
and Metabolism centre, Hull Royal Infirmary, UK. 116 
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Two hundred women were randomised into either the SPI group (15 g soy protein with 117 
66 mg of isoflavones) or SP group (15 g soy protein alone, isoflavone free) daily for a 118 
period of six months, administered as below.   119 
The primary outcome of this study was to assess the plasma bone turnover markers 120 
(13). The secondary outcomes for this study were the assessment of cardiovascular 121 
disease risk markers including insulin resistance, lipids, and hsCRP, but their 122 
assessment within the Framingham risk engine was a new analysis within this dataset.  123 
During study visits (baseline, three months and six months), participants were 124 
instructed to maintain their normal level of physical activity throughout the study. In 125 
addition, participants were required to avoid food products containing soy, alcohol, 126 
vitamin or mineral supplementation, and over-the-counter medications. No other 127 
changes in the diet were recommended. Dietary reinforcement was undertaken at each 128 
visit by a registered dietician, together with measurement of serum isoflavone 129 
concentrations to ensure compliance. There was telephone contact by study personnel, 130 
six and 18 weeks after study visits to ensure compliance. Analysis of compliance with 131 
the study preparation was undertaken by counting the returned sachets. All participants 132 
gave their written informed consent for this study that had been approved by the 133 
Research Ethics Committee (East Yorkshire & North Lincolnshire Research Ethics 134 
Committee, ref: 09/1304/45).    135 
Study product 136 
The intervention comprised a snack bar containing 7.5 g isolated soy protein powder 137 
(Solcon F, Solbar Industries, Israel) with 33 mg of isoflavones (SPI) (Solgen 40, Solbar 138 
Industries, Ashdod, Israel) given twice daily between meals (15 g soy protein and 66 139 
mg of isoflavones per day), or 7.5 g of the isolated soy protein alone given twice daily 140 
(15 g soy protein per day without isoflavones per day) as control (SP). The latter had 141 
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an isoflavone concentration of less than 300 parts per billion following serial alcohol 142 
extraction by Dishman Ltd, India(13); and product isoflavones assayed by FERA, Sand 143 
Hutton, UK(13). Analysis showed the composition of the dose materials to be 54% 144 
genistein, 35% daidzein, and 12% glycitein as aglycones and further confirmed that 145 
90% of phytoestrogens were in the primary glucoside form, with the remaining 10% as 146 
aglycones or acetyl and malonyl glucosides. The soy with and without isoflavones was 147 
analysed using AOCS official method Ba 4d-90 “Nitrogen-ammonia-protein modified 148 
Kjeldahl method titanium dioxide + copper sulphate catalyst” that determines total 149 
nitrogen content and protein. The snack bars were eaten twice daily between meals for 150 
6 months. The soy protein and the isoflavones were from a single batch that was 151 
designated for the study. The study bars were specifically commissioned, prepared (soy 152 
with and without isoflavones, mixed with water and cold compressed into a snack bar) 153 
and packaged by Halo foods, Swindon, UK. Soy bars of similar macronutrient content 154 
were identical in size, shape, texture and both arms were in identical packaging; a taste 155 
panel prior to the study could not distinguish a difference in taste between the 2 156 
preparations. There was no difference in side effects or drop outs that would distinguish 157 
between the 2 products. 158 
 159 
Randomisation 160 
The randomisation was performed by Essential Nutrition Ltd, UK as detailed(13), using 161 
a computer generated randomisation sequence was used to provide balanced blocks of 162 
patient numbers for each of the two treatment groups. Compliance was documented by 163 
return of the empty wrappers and uneaten bars. 164 
Study measurements 165 
 © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/                                   8 
 
During the baseline, three months and six month study visits, and following an over-166 
night fast, anthropometric parameters were measured and blood samples collected, 167 
stored at -80oC and insulin batch analysed at the end of the study. Blood pressure was 168 
measured after the participants had been seated quietly for at least five minutes with the 169 
right arm supported at heart level. Blood pressure measurements were performed using 170 
an automated device (NPB-3900; Nellcor Puritan Bennett, Pleasanton, CA) during each 171 
study visit. Two readings were obtained at the beginning of each visit at least one 172 
minute apart and the average of the readings was taken. Fasting venous blood samples 173 
were collected and prepared as previously described (13). Briefly, blood was separated 174 
by centrifugation at 2000 g for 15 min at 4oC, and the aliquots stored at -80oC within 175 
one hour of collection. Plasma glucose was measured using a Synchron DxC analyzer 176 
(Beckman-Coulter, UK), and serum insulin was assayed using an ultra-sensitive 177 
chemiluminescent one-step immunoenzymetic ‘sandwich’ assay performed on a Unicel 178 
DXi Immunoassay system (Beckman-Coulter, UK). The coefficient of variation (CV) 179 
of this method was 8%, calculated using duplicate study samples. The analytical 180 
sensitivity was 2 µU/mL.  Insulin resistance was calculated using HOMA-IR (Insulin 181 
x glucose)/22.5) (14).  182 
Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL) levels 183 
were measured enzymatically using a Synchron DxC analyzer (Beckman-Coulter, UK). 184 
Low-density lipoprotein cholesterol (LDL) was calculated using the Friedewald 185 
equation. At a mean total cholesterol of 4.9mmol/l combined within and between 186 
(intralab) CV was 0.7%; at a mean HDL of 0.9mmol/l combined within and between 187 
CV was 1.0%; at a mean triglyceride level of 1.61mmol/l combined within and between 188 
CV was 0.94%; at a mean hsCRP of 8.4mmol/l combined within and between CV was 189 
1.1%). 190 
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The isoflavones in serum were extracted and analysed by LGC, Fordham, 191 
Cambridgeshire, UK using isotope-dilution LC-MS/MS (15). LC-MS/MS was 192 
conducted using a Sciex 4000 Qtrap with separation achieved using a C18 column and 193 
mobile phases of water and acetonitrile, both containing acetic acid(16). 194 
The calculated risk scores between groups using the Framingham equation (11) (based 195 
on age, total cholesterol, HDL and systolic blood pressure: smoking and diabetes were 196 
exclusion criteria in this study and therefore set to zero in the calculation) were 197 
performed at 6 months as this was the pre-determined end point of the study 198 
Statistical analysis 199 
Sample size was powered for changes in bone markers and not specifically for 200 
cardiovascular risk (13): a post hoc power analysis for CVR would have been poor 201 
statistical practice and as such was not conducted. An intention to treat analysis was 202 
undertaken; however, the data from withdrawals were included as part of intention-to-203 
treat analysis. Baseline values were not compared statistically given that this was a 204 
randomised controlled trial. For each group (SPI and SP) separately a paired difference 205 
(six-months minus baseline) of means was calculated, the two paired means were then 206 
compared using an independent t-test; the p-value is the probability of the difference of 207 
the difference being a false positive. This is referred to in Table 2 as the 'difference of 208 
the difference' and 95% confidence interval gives the precision of the difference of the 209 
difference in the tables. This difference of the difference at 6 months is reflected in 210 
Figure 1 for the calculated cardiovascular risk. A paired t test for baseline to 3 months 211 
and 3 months to six-months within groups was performed for the metabolic factors and 212 
cardiovascular risk to assess trend. Data was analysed using the Stata statistical 213 
computer package (StataCorp. Stata Statistical Software.  Release 13. College Station, 214 
Texas, 2013).  215 
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Results 217 
120 women completed six months of the study, 60 in the SPI group and 60 in the SP 218 
group with an overall dropout rate of 40%: the main reasons for dropping out of the 219 
study have been detailed previously (13).  220 
The baseline anthropometric, metabolic, plasma isoflavone levels were comparable 221 
between the two groups and may be seen in Table 1.  222 
Serum Diadzein, genistein and equol were increased in the SPI group confirming 223 
compliance (p<0.001) whilst those in the SP group did not differ between baseline, 3 224 
months and 6 months; bone marker concentrations changed significantly during the 225 
study as described elsewhere (13).  Empty wrappers and uneaten bars were returned 226 
and counted by the study team. If compliance was less than 75% then the subject was 227 
to be withdrawn from the study: those that completed the study had a compliance of 228 
more than 90%. 229 
Changes in the metabolic parameters after 6 months are shown in Table 2 with 230 
decreased fasting glucose, fasting insulin and HOMA-IR. Lipid parameters (total 231 
cholesterol, LDL, HDL and triglycerides) and hsCRP were unchanged between 232 
treatment groups. There was a significant reduction in systolic blood pressure at six 233 
months between SP and SPI supplementation though diastolic blood pressure was 234 
unchanged.  (Table 2). 235 
There was no difference in the baseline characteristics of those that dropped out of the 236 
study versus those that completed the study.  237 
 238 
The within group calculation risk at 3 months, and 3 months to 6 months was performed 239 
to determine trend across the time period and is shown in Figure 1. The calculated 10 240 
year risk for coronary heart disease showed a 27% reduction at 6 months comparing 241 
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SPI with SP (p<0.01), though only the within group change for SPI, but not SP, showed 242 
a significant reduction at 3 months and a subsequent further reduction at 6 months. The 243 
calculated 10 year myocardial infarction risk showed a 37% reduction at 6 months 244 
between SPI and SP (p<0.01); the within group change for SPI, but not SP, showed a 245 
significant reduction at 3 months and a subsequent further reduction at 6 months. The 246 
calculated 10 year cardiovascular disease risk showed a 24% reduction at 6 months 247 
between SPI and SP (p<0.04); the within group change for SPI, but not SP, showed a 248 
significant reduction at 3 months and a subsequent further reduction at 6 months. The 249 
calculated 10 year cardiovascular death risk showed a 42% reduction at 6 months 250 
between SPI and SP (p<0.02); the within group change for SPI, but not SP, showed a 251 
significant reduction at 3 months and a subsequent further reduction at 6 months (Figure 252 
1). Stroke and death from coronary heart disease did not differ at 6 months between SP 253 
and SPI treatment (Figure 1); however, it is of interest that risk of stroke decreased 254 
within groups for both the SPI and SP groups.  255 
No one isoflavone measured (genistein, diadzein, equol) in the SPI group showed a 256 
difference in Framingham score compared to each other (p>0.05), and there was no 257 
difference between equol producers (n=38) and equol non-producers (n=22) for 258 
cardiovascular risk (data not shown). The prevalence of equol producers was 19% in 259 
this study which is comparable to that seen in the Caucasian population (9).  260 
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Discussion 261 
The calculation of the CVR parameters showed a significant reduction in calculated 262 
10-year coronary heart disease (27%), myocardial infarction (37%), cardiovascular 263 
risk (24%) and death due to cardiovascular disease (42%) with SPI supplementation 264 
using the Framingham equation (11, 17). This is in accord with an observational study 265 
using dietary recall where high isoflavone intake was associated with reduced risk of 266 
cerebral and myocardial infarction that was more pronounced for postmenopausal 267 
women (5, 18). A Japanese study of the traditional soy food natto showed a decrease 268 
in CVD mortality(6). Others have shown that soy protein along with isoflavone 269 
supplementation may reduce subclinical atherosclerosis in women at low-risk for 270 
cardiovascular disease who were <5 years postmenopausal (7). The effect of the 271 
soy/isoflavones SPI preparation on CVR parameters and indices reflects those seen in 272 
a study using the same preparation in hypogondal men with type 2 diabetes (4). 273 
Stroke risk did not differ at 6 months between SP and SPI treatment; however, it is of 274 
interest that risk of stroke decreased within groups for both the SPI and SP groups. 275 
The risk of cerebral infarction has been noted to decrease with soy intake, particularly 276 
in postmenopausal women (18) and in the natto study, a decrease of stroke was only 277 
seen at the highest quartiles of soy intake, above that of this study(6). A meta-analysis 278 
of eleven trials demonstrated that soy isoflavone intake resulted in a mean decrease of 279 
2.5 mmHg for systolic blood pressure compared to placebo (19); however, there was 280 
significant heterogeneity between the studies. A 4–5 mmHg reduction in systolic 281 
blood pressure can reduce CVD risk by 8–20% (20). In the current study, there was a 282 
3.2mmHg reduction in systolic blood pressure with soy protein and isoflavone 283 
supplementation for 6 months. An improvement in systolic pressure alone was seen in 284 
a study using the same isoflavone preparation with soy protein as here(21), but in a 285 
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study in type 2 diabetes  patients treated with 132mg tablets of isoflavone alone 286 
without soy protein there was no effect on systolic blood pressure (5).   This suggests 287 
that a synergistic matrix effect between the soy protein with the isoflavones may be 288 
responsible for any cardiovascular disease changes since both supplements contains 289 
the same amount of protein.   290 
Given that this was a healthy volunteer population without other cardiovascular 291 
comorbidities and therefore were not likely to have had any additional cardiovascular 292 
risk; thus repeating this study in a population of greater risk may likely see increased 293 
benefits. There were no significant changes for body mass index, diastolic blood 294 
pressure, hsCRP and lipid profile, and the reduction in predicted 10-year 295 
cardiovascular disease risk from the Framingham risk score that was derived from the 296 
decreased systolic blood pressure. 297 
There was a significant reduction in systolic blood pressure with three months of SPI 298 
that did not improve further at 6 months, but no changes were seen with SP, and 299 
diastolic blood pressure remained unchanged with treatment. Participants’ age and 300 
systolic blood pressure are the two most potent risk factors included in the 301 
Framingham risk equation, so although lipids were no different between the groups, 302 
presumably the overall cardiovascular risk calculation was being driven by the 303 
observed SBP difference. 304 
There were no changes in the total cholesterol, LDL, HDL or triglyceride levels by the 305 
soy preparations between groups at 6 months, results that are in accord with others 306 
where the placebo used was cellulose (5) and lipid parameters were unchanged. This is 307 
the converse reported for a soy with a cassein comparator study that reported a 4% 308 
reduction in LDL (22). Reductions in both total cholesterol and LDL, but not HDL were 309 
detailed in a meta-analysis (23), though differences in study design and small study 310 
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numbers, soy preparation, isoflavone composition (glucoside or aglycone forms) would 311 
all contribute to the discrepant findings here and in other studies. However, 15g/day of 312 
soy were used in this study that may have been too little to reduce cholesterol, thought 313 
to be due to the soy protein affect, and a Food and Drug Administration claim called 314 
for 25g/ day to be effective. There were no differences in the cardiovascular risk 315 
parameters between producers and non-producers of equol in accord with the 28 316 
negative studies reported in a recent meta-analysis (24). It is not known whether these 317 
cardiovascular beneficial effects would continue in the future with the cessation of soy 318 
treatment, akin to the metabolic memory seen in diabetes (25),  or would be short term 319 
with only an effect whilst taking the soy preparation.  320 
Dietary intake of isoflavones in Asian soy diets has been estimated to be in the range 321 
of 30-50 mg per day of combined isoflavone aglycone equivalents(26, 27). In Western 322 
countries an average daily intake of approximately 2 mg isoflavones is seen though 323 
estimated to be 16mg in vegetarians(28); therefore, the dose of 66mg of isoflavones 324 
used in this study may be considered to be in the pharmacological range. 325 
The strength of this study is that this study is unique in using a soy preparation well 326 
defined from a single batch that was truly isoflavone free that could determine the 327 
contribution to any cardiovascular disease risk effect by the soy protein alone.  No 328 
treatment effects on the individual parameters were seen for soy protein alone, 329 
suggesting that the soy protein by itself is inactive. Whilst there was no difference in 330 
the protein composition between soy with and without isoflavones following serial 331 
alcohol washing, the serial alcohol washing could have altered the tertiary structure of 332 
the protein and removed other components besides isoflavones. The limitations of this 333 
study include that the cardiovascular disease risk markers were not the primary aim of 334 
the study. However, the study was over powered for the primary outcome and 335 
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analysed as an intention to treat thus minimizing the anticipated dropout rate. The 336 
dropout was around 40% as anticipated so that the power of the study was not 337 
compromised. This approach circumvented the concerns of a potential type 2 error for 338 
the primary variable. Furthermore, the changes in the CVR markers were in accord 339 
with another large study using the same preparation (4). The features of those that 340 
dropped of the study did not differ between groups nor differed to those that 341 
completed. Plasma isoflavone concentrations increased in the SPI alone confirming 342 
compliance, whilst the SP group did not change from baseline excluding exogenous 343 
isoflavone ingestion.  Whilst dietary advice was given at each visit, formal dietary 344 
assessment to determine macronutrient intake was not undertaken so it is possible that 345 
the ingestion of the extra 15g of soy protein may have subtly altered dietary habits 346 
that may have contributed to the results. 347 
In conclusion, there was a beneficial effect on systolic blood pressure with soy and 348 
isoflavone intake over 6 months in this population of women in their early menopause, 349 
and the reduction in systolic blood pressure was reflected in cardiovascular disease risk 350 
calculated by the Framingham equation.  351 
  352 
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Legend to Figure 1 460 
Trend in cardiovascular disease risk reduction with soy protein and isoflavone (SPI) 461 
and soy protein alone (SP) showing the within group changes from baseline to 3 462 
months and from 3 months to 6 months using Framingham criteria. Data show the 463 
progressive fall in the risk parameter over the 6 month period of the study for the SPI 464 
treated group for A), CHD; B), CHD death; D,  MI; E), CVD; F), CVD death, but not 465 
for C), stroke. 466 
CHD – 10 year coronary heart disease risk. MI – 10 year myocardial infarction risk. 467 
Stroke – 10 year stroke risk. CVD – 10 year cardiovascular risk. CHD death – 10 year 468 
risk for death due to coronary heart disease. CVD death – 10 year risk for death due to 469 
cardiovascular disease. Error bars are SEM. 470 
 471 
